Travere Therapeutics(TVTX)
Focus: Travere Therapeutics is a public biotech focused on rare kidney and metabolic diseases with a commercial-stage pipeline centered on sparsentan (FILSPARI). The company operates at mid-cap scale with 201-500 employees and derives all current revenue from a single approved product.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
47-4 this month
Stable — net -4 jobs in 30d
28 added, 32 removed. Backfill posture.
Should You Work at Travere Therapeutics?
AI assessmentTravere offers high-growth rare-disease upside for specialists willing to tolerate single-product revenue risk and tight cash runway—best suited for early/mid-career scientists seeking niche domain depth over financial stability.
Why Work Here
- Active commercial launch of FILSPARI (sparsentan) in nephrology creates immediate revenue growth opportunity—revenue grew 33% YoY ($109M to $145M) with Part D reimbursement established.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Key Products
Peak
Help build intelligence for Travere Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.